BACKGROUND: The purpose of this study was to present our experience utilizing cetuximab and platinum-based concurrent chemoradiotherapy for the definitive treatment of head and neck squamous cell carcinoma (HNSCC). METHODS: Patients (n = 177) who received definitive concurrent chemoradiotherapy for HNSCC were stratified into 3 groups: receiving cetuximab monotherapy (n = 24), cetuximab and chemotherapy combination (n = 33), or platinum-based chemotherapy without cetuximab (n = 120). Primary endpoints were freedom from relapse, event-free survival, and overall survival (OS). RESULTS: Patients receiving cetuximab monotherapy were older with lower Karnofsky performance status (KPS) and higher Charlson comorbidity scores compared with those treated with combination cetuximab and chemotherapy or platinum-based concurrent chemoradiotherapy. Patients treated with platinum-based concurrent chemoradiotherapy exhibited significantly better freedom from relapse, event-free survival, and OS compared with those receiving cetuximab monotherapy or cetuximab and chemotherapy combination therapies (all p < .05). Differences between patients receiving cetuximab monotherapy and platinum-based concurrent chemoradiotherapy held on multivariate Cox regression. CONCLUSION: This study suggests that platinum-based concurrent chemoradiotherapy is superior to cetuximab-based monotherapy for the definitive treatment of HNSCC.
BACKGROUND: The purpose of this study was to present our experience utilizing cetuximab and platinum-based concurrent chemoradiotherapy for the definitive treatment of head and neck squamous cell carcinoma (HNSCC). METHODS:Patients (n = 177) who received definitive concurrent chemoradiotherapy for HNSCC were stratified into 3 groups: receiving cetuximab monotherapy (n = 24), cetuximab and chemotherapy combination (n = 33), or platinum-based chemotherapy without cetuximab (n = 120). Primary endpoints were freedom from relapse, event-free survival, and overall survival (OS). RESULTS:Patients receiving cetuximab monotherapy were older with lower Karnofsky performance status (KPS) and higher Charlson comorbidity scores compared with those treated with combination cetuximab and chemotherapy or platinum-based concurrent chemoradiotherapy. Patients treated with platinum-based concurrent chemoradiotherapy exhibited significantly better freedom from relapse, event-free survival, and OS compared with those receiving cetuximab monotherapy or cetuximab and chemotherapy combination therapies (all p < .05). Differences between patients receiving cetuximab monotherapy and platinum-based concurrent chemoradiotherapy held on multivariate Cox regression. CONCLUSION: This study suggests that platinum-based concurrent chemoradiotherapy is superior to cetuximab-based monotherapy for the definitive treatment of HNSCC.
Authors: Shilpa Bhatia; Jaspreet Sharma; Sanjana Bukkapatnam; Ayman Oweida; Shelby Lennon; Andy Phan; Dallin Milner; Nomin Uyanga; Antonio Jimeno; David Raben; Hilary Somerset; Lynn Heasley; Sana D Karam Journal: Clin Cancer Res Date: 2018-05-30 Impact factor: 12.531
Authors: William A Stokes; Whitney A Sumner; Kiersten L Breggren; John T Rathbun; David Raben; Jessica D McDermott; Gregory Gan; Sana D Karam Journal: Rep Pract Oncol Radiother Date: 2017-08-02
Authors: Maura L Gillison; Andy M Trotti; Jonathan Harris; Avraham Eisbruch; Paul M Harari; David J Adelstein; Richard C K Jordan; Weiqiang Zhao; Erich M Sturgis; Barbara Burtness; John A Ridge; Jolie Ringash; James Galvin; Min Yao; Shlomo A Koyfman; Dukagjin M Blakaj; Mohammed A Razaq; A Dimitrios Colevas; Jonathan J Beitler; Christopher U Jones; Neal E Dunlap; Samantha A Seaward; Sharon Spencer; Thomas J Galloway; Jack Phan; James J Dignam; Quynh Thu Le Journal: Lancet Date: 2018-11-15 Impact factor: 79.321
Authors: Chad Tang; Clifton D Fuller; Adam S Garden; Musaddiq J Awan; Rivka R Colen; William H Morrison; Steven J Frank; Beth M Beadle; Jack Phan; Erich M Sturgis; Mark E Zafereo; Randal S Weber; David I Rosenthal; G Brandon Gunn Journal: Oral Oncol Date: 2014-11-28 Impact factor: 5.337
Authors: Shrujal S Baxi; Caitriona O'Neill; Eric J Sherman; Coral L Atoria; Nancy Y Lee; David G Pfister; Elena B Elkin Journal: Head Neck Date: 2015-06-26 Impact factor: 3.147